Volitinib Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Savolitinib selectively inhibits the MET receptor, blocking the PI3K/AKT/MAPK-signaling pathway as well as downregulating MYC.

Verwenden

Savolitinib is a potent and highly selective c-Met inhibitor. Savoltinib demonstrated anti-tumor efficacy in a panel of cMet-dysregulated gastric cancer PDX models. Savolitinib also demonstrated good antitmuor activities.

Clinical Use

It is currently being evaluated in phase I clinical trials in combination with EGFR TKIs in NSCLC patients.

Volitinib Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Volitinib Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
ATK CHEMICAL COMPANY LIMITED	+undefined-21-51877795	ivan@atkchemical.com	China	32956	60
Hubei xin bonus chemical co. LTD	86-13657291602	linda@hubeijusheng.com	CHINA	22963	58
BOC Sciences	+1-631-485-4226	inquiry@bocsci.com	United States	19553	58
Chongqing Chemdad Co., Ltd	+86-023-6139-8061 +86-86-13650506873	sales@chemdad.com	China	39894	58
career henan chemical co	+86-0371-86658258 +8613203830695	factory@coreychem.com	China	29810	58
Hebei Mujin Biotechnology Co.,Ltd	+86 13288715578 +8613288715578	sales@hbmojin.com	China	12830	58
Dideu Industries Group Limited	+86-29-89586680 +86-15129568250	1026@dideu.com	China	22787	58
Sinoway Industrial co., ltd.	0592-5800732; +8613806035118	xie@china-sinoway.com	China	988	58
Zhejiang J&C Biological Technology Co.,Limited	+1-2135480471 +1-2135480471	sales@sarms4muscle.com	China	10473	58
Hong Kong Tiansheng New Material Trading Co., Ltd	+8617320695765	zxx@hktiansheng.com	China	973	58

---

• AZD6094,Volitinib, HMPL-504, Savolitinib
• 1-[(1S)-1-Imidazo[1,2-a]pyridin-6-ylethyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-1,2,3-triazolo[4,5-b]pyrazine
• (S)-1-(1-(imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine
• Volitinib
• HMPL-504(AZD6094, Volitinib)
• EOS-60799
• AZD-6094)
• Savolitinib (Volitinib
• (S)-1-(1-(imidazo[1,2-a] yridine-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine
• (S)-1-(1-(IMIDAZO[1,2-A]
• HMPL-504; HMPL504; HMPL504; AZD-6094; AZD 6094; AZD6094
• Volitinib (Savolitinib, AZD-6094)
• CS-2676
• VOLITINIB; HMPL504; AZD-6094;VOLITINIB; HMPL-504; AZD6094; HMPL 504; AZD 6094
• Savolitinib(AZD6094, HMPL-504)
• 1H-1,2,3-Triazolo[4,5-b]pyrazine, 1-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-6-(1-methyl-1H-pyrazol-4-yl)-
• Volitinib USP/EP/BP
• 4-{1-[(1S)-1-{imidazo[1,2-a]pyridin-6-yl}ethyl]-1H-[ 1,2,3]triazolo[4,5-b]pyrazin-6-yl}-1-methyl-1H-pyra zole
• Savolitinib
• HMPL-504
• Savolitinib (AZD6094)
• Pharmaceutical Intermediate Volitinib
• AZD-6094 (VOLITINIB)
• VOLITINIB (AZD6094, SAVOLITINIB)
• HMPL0-504
• 1313725-88-0
• API